Literature DB >> 7496339

Development of a new Er: YAG laser conception for laser sclerostomy ab externo: experimental and first clinical results.

W Wetzel1, R Otto, W Falkenstein, U Schmidt-Erfurth, R Birngruber.   

Abstract

The erbium:YAG laser is a preferable energy source for laser sclerostomy ab externo due to the high absorption of its radiation (2940-nm wavelength) in the aqueous parts of scleral tissue. It has thus far been a disadvantage that laser energy has to be transmitted from the laser source to the application site via very susceptible special optical fibers (ZrF). As a consequence of technical improvements, the laser source could be integrated into the application probe. Therefore, only a robust quartz fiber was necessary for contact application. A fiber diameter of 400 microns was chosen according to the experience gained in previous studies. A total of 24 eyes with chronical open-angle glaucoma were treated. A fistula end-point detection unit was developed for safe indication of a full-thickness perforation of the sclera. With a fiber diameter of 400 microns, a postoperative success rate of about 54% was achieved at 6 months follow-up. The automated full-thickness perforation detection prevented the application of additional, surplus laser pulses in the anterior chamber. The postoperative success rate could be improved over that achieved in previous studies. The new device/conception offers more technical reliability and is a further step toward minimally invasive fistulating laser surgery of open-angle glaucoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7496339

Source DB:  PubMed          Journal:  Ger J Ophthalmol        ISSN: 0941-2921


  2 in total

1.  Evaluation of carbon dioxide laser therapy for benign tumors of the eyelid margin.

Authors:  Aniko Rentka; Jan Grygar; Zoltan Nemes; Adam Kemeny-Beke
Journal:  Lasers Med Sci       Date:  2017-09-02       Impact factor: 3.161

2.  Experimental studies on nonpenetrating filtration surgery using the CO2 laser.

Authors:  Ehud I Assia; Yigal Rotenstreich; Irina S Barequet; David J Apple; Mordechai Rosner; Michael Belkin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-13       Impact factor: 3.535

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.